Kona Medical Release: Six Month Data Reported for WAVE I Study of Renal Denervation Therapy for Hypertension at EuroPCR Meeting in Paris
5/23/2013 10:26:48 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BELLEVUE, Wash. & MENLO PARK, Calif.--(BUSINESS WIRE)--Kona Medical announced that three and six month results from the WAVE I study were presented today at the late-breaking clinical trials session of EuroPCR in Paris by Robert Whitbourn, MD, of St. Vincent’s Hospital in Melbourne, Australia. WAVE I is a first-in-man study evaluating the safety and efficacy of Kona Medical’s Surround Sound® Renal Denervation System for the treatment of resistant hypertension. Unlike other renal denervation methods which rely on a catheter emitting energy through the wall of the renal artery, Kona’s system delivers ultrasound energy to the nerves from outside the body. This targeted energy “surrounds” the artery and treats the nerves located in the vicinity of the vessel. Data presented from WAVE I demonstrated that patients treated with the Surround Sound® Renal Denervation System had no device-related serious adverse events and experienced a 22 mmHg drop in systolic blood pressure and 9 mmHg drop in diastolic blood pressure at three months (N=24). In those patients who had reached 6 months follow up (N=14) there was a 29 mmHg drop in systolic blood pressure and 9 mmHg drop in diastolic blood pressure.
Help employers find you! Check out all the jobs and post your resume.
comments powered by